Abstract:BACKGROUND:Schizophrenic patients treated with antipsychotic drugs (AP) have an increased frequency of glucose-lipid metabolic abnormalities and diabetes. Pioglitazone has been shown to be effective in the treatment of glucose and lipid abnormalities in diabetes and decreasing longer-term conversion of impaired glucose tolerance to frank diabetes. Some studies also suggest possible pro-cognitive and antidepressant effects of pioglitazone. We studied the effects of pioglitazone on potential metabolic, symptomatic and cognitive benefits in schizophrenic patients treated with AP.METHODS:54 schizophrenic patients with at least both a)impaired glucose and b) triglycerides≥120mg/dL and/or low HDL levels, participated in a double-blind placebo controlled study of 3month treatment with Pioglitazone (30-45mg/day) or matched placebo, at 5 sites (4 U.S., 1 China). Fasting glucose and lipid parameters, and psychopathology (PANSS scale) were assessed monthly, and patients had a glucose tolerance test and cognitive testing (RBANS and CPT) at baseline and at the end of study. Statistical analysis used mixed model repeated measures analysis, supplemented by completer and LOCF analysis.RESULTS:In the total sample there was an overall effect (P's<.05 to <.01) of pioglitazone on preventing deterioration in fasting glucose and improving HDL and PANSS depression scores; in the pioglitazone group comparison of baseline vs 3month values also showed significant (P<.05) decreases in fasting insulin, 2h glucose in GTT and insulin resistance (HOMA-IR). However there were marked differences between the responses of patients in the U.S. sites vs the China site. In the U.S. sample, patients treated with pioglitazone, when compared to placebo treated patents, had significantly lower fasting glucose (F=3.99, P=0.02), improved insulin sensitivity (lower H0MA-IR, F=6.24, P=.002), lower triglycerides (F=2.68, P=.06) and increased HDL (F=6.50, P=.001). By the end of the study 52% of the pioglitazone treated patients compared to 15% of the placebo patients had fasting glucose in the normal range (Fisher's exact test P=.02). Pioglitazone also significantly improved PANSS depression factor scores (F=2.82, P=0.05). It did not improve cognitive performance on the RBANS or CPT tasks. Pioglitazone did not increase weight or produce any other significant side-effects. In the small mainland China site sample, pioglitazone treatment, as compared to placebo, did not show greater improvement in metabolic parameters or psychopathology ratings.CONCLUSIONS:In the sample of patients from the U.S., pioglitazone was an efficacious and safe treatment for glucose and lipid metabolic abnormalities in schizophrenic patients treated with AP, and it may also have beneficial effects on depressive symptoms. It may be particularly useful in patients whose weight gain effects from antipsychotics have plateaued and where weight loss is not the primary goal. The risk vs. benefits of longer term treatment with pioglitazone has to be carefully evaluated for individual patients.

Adjuvant Pitolisant in a Case With Early-Onset Schizophrenia

Effects of paliperidone extended-release tablets (paliperidoneer) and olanzapine on metabolic profile, weight, insulin resistance and beta-cell function in schizophrenic patients: a randomized 12-week study

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

A Randomized, 13-Week Study Assessing the Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

Aripiprazole Augmentation in Managing Comorbid Obsessive-Compulsive Disorder and Bipolar Disorder: a Case with Suicidal Attempts.

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients

Metabolic Effects Of 7 Antipsychotics On Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice

Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model

The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children

0631 Phase 2, Proof-of-Concept Study of Pitolisant in Prader-Willi Syndrome: Primary and Secondary Efficacy Analyses

Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone)

Pharmacological Add-On Treatments for Short-Term Control of Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis

Olanzapine-Induced Weight Gain and Glycolipid Metabolism Aberrations in First-Episode and Antipsychotic-Naïve Schizophrenia Patients: A Longitudinal Study

Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study

Effects of Pioglitazone on Metabolic Abnormalities, Psychopathology, and Cognitive Function in Schizophrenic Patients Treated with Antipsychotic Medication: a Randomized Double-Blind Study.

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

New discoveries for an old drug: a review of recent olanzapine research

The combined pioglitazone and topiramate therapy for management of pediatric patients with severe MASLD